Abstract:BACKGROUND:Survivin is known to be overexpressed in various human malignancies, including pancreatic cancer, and mediates cancer cell proliferation and tumor growth, so the regulation of this molecule could be a new strategy for treating pancreatic cancer. In this study, short hairpin RNAs (shRNAs) specific to survivin were introduced into human pancreatic cancer Patu8988 cells to investigate the inhibitory effects on survivin expression and cell proliferation in vitro and in vivo.METHODS:Three kinds of shRNA specific to the survivin gene were designed and cloned into eukaryotic expression plasmid pGenesil-1 vector. Subsequently the recombinant plasmids were transfected into human pancreatic cancer Patu8988 cells with lipfectamineTM 2000 reagent. The mRNA and protein expressions of survivin in the transiently transfected Patu8988 cells were determined by RT-PCR, flow cytometry, and Western blotting analysis. The proliferation inhibition rates of stably transfected Patu8988 cells were determined by MTT assay. The antitumor activities of the three kinds of survivin-shRNA plasmids were evaluated in BALB/c nude mice inoculated with Patu8988 cells and bearing human pancreatic cancer.RESULTS:The three survivin-shRNA plasmids named pGenesil-1-survivin-1, pGenesil-1-survivin-2 and pGenesil-1-survivin-1+2 (with double interfering RNA sites) were successfully constructed, and were confirmed by restriction enzyme cutting and sequencing. At 48 hours after transfection, the expression of survivin mRNA and protein was inhibited in Patu8988 cells transfected with pGenesil-1-survivin-1, pGenesil-1-survivin-2, and pGenesil-1-survivin-1+2 when compared with that of either pGenesil-1-NC (with scrambled small interfering RNA) transfected cells or control cells (P<0.05). The MTT results showed that the proliferation rates of Patu8988 cells stably transfected with survivin-shRNA plasmids were reduced when compared with that of either pGenesil-1-NC transfected cells or control cells (P<0.01). Furthermore, when Patu8988 cells stably transfected with survivin-shRNA were injected into BALB/c nude mice, tumor growth was dramatically lower and the tumor was smaller than that of either pGenesil-1-NC transfected cells or control cells (P<0.01). The inhibitory effect of pGenesil-1-survivin-1 was the best among the three kinds of survivin-shRNA plasmids, but no combination of inhibitory effects was found in pGenesil-1-survivin-1+2.CONCLUSIONS:shRNAs specific to survivin have gene silencing effects and inhibit pancreatic cancer cell proliferation. shRNA activity against survivin could be of potential value in gene therapy for pancreatic cancer. However, shRNAs with double combining sites did not significantly enhance the interference compared with single site shRNAs, therefore further studies on this are needed.

Mechanisms of Inhibition of Growth of Human Pancreatic Carcinoma Implanted in Nude Mice by Somatostatin Receptor Subtype 2

[Mechanisms of Inhibition of Growth of Human Pancreatic Carcinoma Implanted in Nude Mice by Somatostatin Receptor Subtype 2].

Anti-angiogenic effects of somatostatin receptor subtype 2 on human pancreatic cancer xenografts.

Gene Transfer of Somatostatin Receptor Type 2 by Intratumoral Injection Inhibits Established Pancreatic Carcinoma Xenografts

Antiangiogenic Effect of Somatostatin Receptor Subtype 2 on Pancreatic Cancer Cell Line: Inhibition of Vascular Endothelial Growth Factor and Matrix Metalloproteinase-2 Expressionin Vitro

Anti-migratory and anti-invasive effect of somatostatin receptor type2 gene in human pancreatic carcinoma cell

Inhibition of Metastatic Progression of SSTR2 Gene Transfection Mediated by Adenovirus in Human Pancreatic Carcinoma Cells

Adenoviral-mediated Somatostatin Receptor Subtype 2 Gene Transfer Inhibits Pancreatic Cancer Xenografts

Overexpression of SSTR2 inhibited the growth of SSTR2-positive tumors via multiple signaling pathways.

Inhibition Effect of Somatostatin on the Growth of Human Pancreatic Carcinoma Cell Line

Mechanism of octreotide reversing multidrug resistance in human pancreatic cancer cell line BxPC - 3

Anti-carcinoma Effect of Targeted Radiotherapy Using 90Y-Dota-octreotide Mediated by Somatostatin Receptor

Effect of Octreotide on Human Pancreatic Cancer Cells after Transfected with Somatostatin Receptor Type 2 Gene

Alteration of Somatostatin Receptor Subtype 2 Gene Expression in Pancreatic Tumor Angiogenesis.

Mrna Expression of Somatostatin Receptor Subtypes SSTR-2, SSTR-3, and SSTR-5 and Its Significance in Pancreatic Cancer

Hsstr 2 Expression and Octreotide Treatment Reverses Multidrug Resistance of BxPC-3 Human Pancreatic Cancer Cells

Mechanisms and influence of octreotide-induced regulation of somatostatin receptor 2 on hepatocellular carcinoma.

[Expression of Somatostatin Receptor Reporter Gene and Its Correlation with Targeted Imaging in Vivo for Detection of Pancreas Carcinoma].

The Effect of Octreotide on Growth Inhibition of Subcutaneous Implanted Tumor with Human Gallbladder Carcinoma in Nude Mice

Growth Inhibition Induced by Short Hairpin RNA to Silence Survivin Gene in Human Pancreatic Cancer Cells.

Effect of angiostatin gene on growth and metastasis of pancreatic carcinoma strain PC-3 orthotopic implantation model in mice